flanders.bio provides you with insights in the vibrant life sciences sector

 

News from flanders.bio and its members

Mithra Signs Agreement for Commercialization of Myring™ in China with Abbott

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into an exclusive license and commercialization agreement with Abbott for the registration and launch of its hormonal contraceptive ring Myring™ in China.

Entrepreneurship | 14 October 19
Read more
14
Oct
2019

Mithra Signs Agreement for Commercialization of Myring™ in China with Abbott

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into an exclusive license and commercialization agreement with Abbott for the registration and launch of its hormonal contraceptive ring Myring™ in China.

14
Oct
2019

Official launch of OHMX.bio, partner for high-throughput OMICS solutions

Novalis and Ghent University are proud to release OHMX.bio, the sixth instalment in Novalis’ portfolio of biotechnology and life sciences related companies. OHMX.bio is a Ghent based company that provides a complete R&D platform helping customers resolve their biological questions
through cutting-edge technologies in different -omics fields: (epi)genomics, transcriptomics, translatomics and proteomics.

11
Oct
2019

Gilead and Galapagos announce efficacy and safety results of filgotinib through 52 weeks in finch 1 and finch 3 studies in rheumatoid arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year.

9
Oct
2019

Mithra Initiates Phase III Clinical Program for Donesta®

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the launch of the Donesta® Phase III clinical program called “E4 Comfort”, with the recruitment of the first patient for the North American Phase III study with E4 monotherapy. Donesta® is a next generation orally-administered E4-based hormone therapy product candidate for the relief of vasomotor menopausal symptoms (VMS).

9
Oct
2019

Novalis participates in financing round of FERTIGA for further expansion of the Corona Test

The Belgian female fertility company Fertiga announces the closure of its first financing round together with Novalis Biotech Incubation and international private investors.

14
Oct
2019

Mithra Signs Agreement for Commercialization of Myring™ in China with Abbott

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into an exclusive license and commercialization agreement with Abbott for the registration and launch of its hormonal contraceptive ring Myring™ in China.

14
Oct
2019

Official launch of OHMX.bio, partner for high-throughput OMICS solutions

Novalis and Ghent University are proud to release OHMX.bio, the sixth instalment in Novalis’ portfolio of biotechnology and life sciences related companies. OHMX.bio is a Ghent based company that provides a complete R&D platform helping customers resolve their biological questions
through cutting-edge technologies in different -omics fields: (epi)genomics, transcriptomics, translatomics and proteomics.

11
Oct
2019

Gilead and Galapagos announce efficacy and safety results of filgotinib through 52 weeks in finch 1 and finch 3 studies in rheumatoid arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year.

9
Oct
2019

Mithra Initiates Phase III Clinical Program for Donesta®

Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the launch of the Donesta® Phase III clinical program called “E4 Comfort”, with the recruitment of the first patient for the North American Phase III study with E4 monotherapy. Donesta® is a next generation orally-administered E4-based hormone therapy product candidate for the relief of vasomotor menopausal symptoms (VMS).

9
Oct
2019

Novalis participates in financing round of FERTIGA for further expansion of the Corona Test

The Belgian female fertility company Fertiga announces the closure of its first financing round together with Novalis Biotech Incubation and international private investors.

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?